Copyright
©The Author(s) 2018.
World J Gastroenterol. Jan 28, 2018; 24(4): 484-493
Published online Jan 28, 2018. doi: 10.3748/wjg.v24.i4.484
Published online Jan 28, 2018. doi: 10.3748/wjg.v24.i4.484
Table 1 Baseline patient characteristics and comparison of disease control rate between different baseline characteristics
Characteristic | Overall (n = 95) | CR + PR + SD (n = 60) | DCR (63.2) | P value2 |
Sex | 1.000 | |||
Male | 88 | 56 | 63.6 | |
Female | 7 | 4 | 57.1 | |
Age (yr)1 | 48.2 ± 11 | 0.390 | ||
< 60 | 80 | 52 | 65 | |
≥ 60 | 15 | 8 | 53.3 | |
α-fetoprotein level (ng/mL) | 0.822 | |||
< 400 | 42 | 26 | 61.9 | |
≥ 400 | 53 | 34 | 64.2 | |
ECOG performance | 0.752 | |||
0 | 66 | 41 | 62.1 | |
1 | 29 | 19 | 65.5 | |
Hepatitis B | 0.745 | |||
No | 5 | 4 | 80 | |
Yes | 90 | 56 | 62.2 | |
Previous TACE | 0.019 | |||
No | 58 | 42 | 72.4 | |
Yes | 37 | 18 | 48.6 | |
Ascites | 0.719 | |||
Absent | 52 | 32 | 61.5 | |
Present | 43 | 28 | 65.1 | |
Child-Pugh classification | 0.373 | |||
A | 80 | 49 | 61.3 | |
B | 15 | 11 | 73.3 | |
PVTT | 0.010 | |||
Absent | 49 | 37 | 75.5 | |
Present | 46 | 23 | 50 | |
Extrahepatic metastasis | 0.103 | |||
No | 69 | 47 | 68.1 | |
Yes | 26 | 13 | 50 | |
Number of tumor | 0.952 | |||
1 | 16 | 10 | 62.5 | |
≥ 2 | 79 | 50 | 63.3 | |
Maximum tumor diameter (cm)1 | 9.5 ± 4.5 | 1.000 | ||
≤ 3 | 9 | 6 | 66.7 | |
> 3 | 86 | 54 | 62.8 |
Table 2 Univariate Cox proportional hazards regression analysis for overall survival
Factor | HR (95%CI) | P value |
Sex (Male/Female) | 1/0.723 (0.314-1.666) | 0.446 |
Age (< 60/≥ 60 yr) | 1/1.233 (0.698-2.179) | 0.470 |
α-fetoprotein (< 400/≥ 400 ng/mL) | 1/1.279 (0.821-1.995) | 0.277 |
ECOG performance (0/1) | 1/1.058 (0.645-1.735) | 0.824 |
Hepatitis B (No/Yes) | 1/2.665 (0.653-10.874) | 0.172 |
Previous TACE (No/Yes) | 1/2.997 (1.831-4.903) | < 0.001 |
Ascites (Absent/ Present) | 1/1.440 (0.922-2.250) | 0.109 |
Child-Pugh classification (A/B) | 1/1.342 (0.751-2.400) | 0.321 |
PVTT (Absent/ Present) | 1/2.678 (1.697-4.227) | < 0.001 |
Absent | 1.000 | |
Main PVTT | 19.206 (8.436-43.727) | < 0.001 |
Branch PVTT | 2.246 (1.386-3.639) | 0.001 |
Extrahepatic metastasis (No/Yes) | 1/1.910 (1.182-3.087) | 0.008 |
Number of tumor (1/≥ 2) | 1/1.125 (0.620-2.043) | 0.698 |
Maximum tumor diameter (≤ 3/> 3 cm) | 1/1.029 (0.472-2.244) | 0.944 |
Early disease control (No/Yes) | 1/0.362 (0.227-0.577) | < 0.001 |
Table 3 Multivariate Cox proportional hazards regression analysis for overall survival
Factor | HR (95%CI) | P value |
Previous TACE | ||
No | 1 | |
Yes | 2.552 (1.477-4.412) | 0.001 |
PVTT | ||
Absent | 1 | |
Present | 2.582 (1.608-4.146) | < 0.001 |
Early disease control | ||
No | 1 | |
Yes | 0.564 (0.339-0.936) | 0.027 |
Extrahepatic metastasis | ||
No | 1 | |
Yes | 1.193 (0.680-2.092) | 0. 538 |
Table 4 Adverse events related to sorafenib
Adverse event | All events | Grade 1-2 events | Grade 3 or higher events |
Hand-foot skin reactions | 78 (82.1) | 67 (70.5) | 11 (11.6) |
Diarrhea | 71 (74.7) | 62 (65.3) | 9 (9.5) |
Hypertension | 10 (10.5) | 8 (8.4) | 2 (2.1) |
Alopecia | 29 (30.5) | 29 (30.5) | 0 |
Fatigue | 29 (30.5) | 29 (30.5) | 0 |
Voice change | 1 (1.1) | 1 (1.1) | 0 |
Gastrointestinal hemorrhage | 7 (7.4) | 0 | 7 (7.4) |
Epistaxis | 1 (1.1) | 1 (1.1) | 0 |
Table 5 Adverse events related to transarterial chemoembolization
Adverse event | All events | Grade 1-2 events | Grade 3 or higher events |
New ascites | 25 (26.3) | 18 (19.0) | 7 (7.3) |
Liver dysfunction | 30 (31.6) | 22 (23.2) | 8 (8.4) |
Pleural effusion | 10 (10.5) | 8 (8.4) | 2 (2.1) |
Spontaneous bacterial peritonitis | 6 (6.3) | 3 (3.2) | 3 (3.2) |
Gastrointestinal hemorrhage | 6 (6.3) | 6 (6.3) | |
Inguinal haematoma | 5 (5.3) | 5 (5.3) | |
Hepatorenal syndrome | 1 (1.1) | 1 (1.1) | |
Ischemic cholecystitis | 1 (1.1) | 1 (1.1) |
- Citation: Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018; 24(4): 484-493
- URL: https://www.wjgnet.com/1007-9327/full/v24/i4/484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i4.484